Introduction & Objective: Factors affecting insulin dose for adults with T2D on MDI are less known. This retrospective observational study evaluated potential factors impacting TDD.

Methods: US adults (≥18 years old) with T2D using MDI (defined as basal and prandial insulin, ≥3 daily injections) were included from the IQVIA ambulatory electronic medical record dataset (01/2017 - 07/2022). The TDD was calculated at first evidence of MDI (index). We used a generalized linear model regression analysis with log link functions to model the relationship between TDD and clinically relevant factors affecting TDD.

Results: Analyses included 41,215 adults with T2D (52% female; 62% Caucasian,14% African-American; mean [±SD] age 58±13 yr, mean BMI 34±7 kg/m2). Mean TDD was 96±58 U; and 23% of adults were using TDD <50 U/day; 41%, 50-100 U/day; 21%, 100-150 U/day; and 15% >150 U/day. Significant predictors of lower TDD were female sex (vs males; incident rate ratio (IRR)=0.93, p<0.001; interpreted as 7% lower on average), African-American race (vs white; IRR=0.85, p<0.001), US Census Regions other than the South (vs South; IRR=0.81-0.92, p<0.001), utilization of sulfonylureas or metformin in 6-month pre-index period (IRR=0.94-0.95, p<0.01), and utilization of 2-3 additional diabetes medications (regardless of class) in pre-index period (vs MDI only; IRR=0.80-0.92, p<0.05). Predictors of greater TDD included age 30-64 yr (vs ≥65 years; IRR=1.07-1.12, p<0.001; interpreted as 7-12% greater on average), increased BMI (IRR=1.03, p<0.001; 3% for each unit increase in BMI, p<0.001) and utilization of GLP1 or SGLT2 in 6-month pre-index period (IRR=1.08-1.12, p<0.001).

Conclusions: Among adults with T2D receiving MDI, the mean TDD was 96±58 U. Significant predictors of TDD included both demographic and clinical characteristics (e.g., race, sex, BMI) and utilization of other diabetes medications.

Disclosure

V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. E.E. Wright: Advisory Panel; Abbott. Consultant; Abbott. Speaker's Bureau; Abbott. Consultant; Abbott Diagnostics. Advisory Panel; ADA/ACC Diabetes by Heart Program, Bayer Inc. Consultant; Bayer Inc. Speaker's Bureau; Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Consultant; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Advisory Panel; Lilly Diabetes. Consultant; Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Advisory Panel; embecta. Consultant; embecta, GlaxoSmithKline plc. Speaker's Bureau; GlaxoSmithKline plc. Advisory Panel; Medtronic, Renalytix. Consultant; Renalytix. Speaker's Bureau; Renalytix. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Advisory Panel; Stability Health. Consultant; Up-To-Date. A.V. Thach: Employee; embecta. Research Support; dQ&A. Employee; AbbVie Inc., Sunovion Pharmaceuticals Inc. E. Miller: Advisory Panel; Abbott, American Diabetes Association. Speaker's Bureau; Boehringer-Ingelheim, Bayer Inc., Eli Lilly and Company. Advisory Panel; embecta, Insulet Corporation, LifeScan Diabetes Institute, Novo Nordisk, Sanofi-Aventis U.S. P. Javadi: Employee; embecta, Insulet Corporation. S. Davies: None. E. Bauer: None. R. Sieradzan: Employee; embecta. Stock/Shareholder; embecta.

Funding

Research study funded by embecta

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.